Inogen (INGN) Capital Expenditures Growth (1y) (2014 - 2026)
Inogen (INGN) Capital Expenditures Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 184.10 Bn | 176.81 Bn | 6.27 Bn | -17.56% |
| 2 | Stryker | 128.79 Bn | 125.91 Bn | 3.81 Bn | 34.96% |
| 3 | Medtronic | 108.97 Bn | 99.75 Bn | 6.41 Bn | 6.32% |
| 4 | Boston Scientific | 68.57 Bn | 67.12 Bn | 3.61 Bn | -5.35% |
| 5 | Edwards Lifesciences | 47.64 Bn | 43.97 Bn | 1.29 Bn | 15.89% |
| 6 | GE HealthCare Technologies | 28.40 Bn | 26.11 Bn | 1.98 Bn | 106.98% |
| 7 | Dexcom | 28.32 Bn | 27.20 Bn | 750.30 Mn | -11.95% |
| 8 | Smith & Nephew | 26.94 Bn | 26.36 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.33 Bn | 2.07 Bn | -47.73% |
| 10 | Inogen | 174.32 Mn | 64.15 Mn | 37.86 Mn | -601.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -601.03% |
| Dec 31, 2025 | 32.39% |
| Sep 30, 2025 | -112.33% |
| Jun 30, 2025 | -94.60% |
| Mar 31, 2025 | 192.00% |
| Dec 31, 2024 | -857.43% |
| Sep 30, 2024 | 11.62% |
| Jun 30, 2024 | 2,963.64% |
| Mar 31, 2024 | 312.77% |
| Dec 31, 2023 | -232.58% |
| Sep 30, 2023 | 163.14% |
| Jun 30, 2023 | -105.06% |
| Mar 31, 2023 | -103.44% |
| Dec 31, 2022 | 79.25% |
| Sep 30, 2022 | -691.27% |
| Jun 30, 2022 | 3,322.22% |
| Mar 31, 2022 | 3,431.71% |
| Dec 31, 2021 | 81.57% |
| Sep 30, 2021 | 117.46% |
| Jun 30, 2021 | -100.97% |